




PHARMACEUTICAL 2021

RespireRx Pharmaceuticals Inc.
Rank 387 of 402





PHARMACEUTICAL 2021

RespireRx Pharmaceuticals Inc.
Rank 387 of 402

The relative strengths and weaknesses of RespireRx Pharmaceuticals Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of RespireRx Pharmaceuticals Inc. compared to the market average is the variable Liabilities, Current, increasing the Economic Capital Ratio by 462% points. The greatest weakness of RespireRx Pharmaceuticals Inc. is the variable Assets, Current, reducing the Economic Capital Ratio by 272% points.

The company's Economic Capital Ratio, given in the ranking table, is -441%, being 489% points below the market average of 47%.

Input Variable	Value in 1000 USD
Assets, Current	85
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	8,148
Liabilities, Non-Current	0
Other Assets	0
Other Compr. Net Income	0
Other Expenses	546
Other Liabilities	0
Other Net Income	-440
Other Revenues	0
Property and Equipment	0
Research and Development	638
Selling, General and Administrative Expense	2,677

Output Variable	Value in 1000 USD
Assets	85
Liabilities	8,148
Expenses	3,861
Revenues	0
Stockholders Equity	-8,063
Net Income	-4,301
Comprehensive Net Income	-4,301
Economic Capital Ratio	-441%